Featured Press Releases

Dr. Scott Grady Makes Thyroid RFA More Accessible in Oregon

Dr. Scott Grady Makes Thyroid RFA More Accessible in Oregon

Jazz Pharmaceuticals announces the U.S. FDA approval of Modeyso™ (dordaviprone) as the first and only treatment for recurrent H3 K27M-mutant diffuse midline glioma

Jazz Pharmaceuticals announces the U.S. FDA approval of Modeyso™ (dordaviprone) as the first and only treatment for recurrent H3 K27M-mutant diffuse midline glioma

  • 07 Aug 2025

Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) has granted...

Vertex Shares New Data on ALYFTREK® Benefits and Sweat Chloride Reduction

Vertex Shares New Data on ALYFTREK® Benefits and Sweat Chloride Reduction

Leqembi® has received approval for intravenous maintenance treatment in China

Leqembi® has received approval for intravenous maintenance treatment in China

UCB to acquire Candid Therapeutics, strengthening its immunology pipeline with novel T-cell engagers

UCB to acquire Candid Therapeutics, strengthening its immunology pipeline with novel T-cell engagers

Menarini Group Shares New Data on ELZONRIS® (tagraxofusp-erzs)

Menarini Group Shares New Data on ELZONRIS® (tagraxofusp-erzs)

Johnson & Johnson Strengthens European Cardiac Care with the Introduction of the Dual Energy THERMOCOOL SMARTTOUCH SF Ablation Platform

Johnson & Johnson Strengthens European Cardiac Care with the Introduction of the Dual Energy THERMOCOOL SMARTTOUCH SF Ablation Platform

  • Johnson & Johnson
  • 25 Jun 2026
StatLab Introduces CytoPath Disc, Enhancing Global Standards in Cell Block Preparation

StatLab Introduces CytoPath Disc, Enhancing Global Standards in Cell Block Preparation

  • StatLab Medical Products
  • 25 Jun 2026
FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

  • Ionis Pharmaceuticals, Inc.
  • 24 Jun 2026
FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

  • Ionis Pharmaceuticals, Inc.
  • 24 Jun 2026
Zeta Surgical® has announced the successful treatment of the first patient using its Zeta TMS Navigation System at HOPE Therapeutics.

Zeta Surgical® has announced the successful treatment of the first patient using its Zeta TMS Navigation System at HOPE Therapeutics.

  • Zeta Surgical
  • 23 Jun 2026
Upsher-Smith Expands KYMBEE™ (Deflazacort) Family of Products with Launch of Oral Suspension for the Treatment of Duchenne Muscular Dystrophy

Upsher-Smith Expands KYMBEE™ (Deflazacort) Family of Products with Launch of Oral Suspension for the Treatment of Duchenne Muscular Dystrophy

  • Upsher-Smith Laboratories, LLC
  • 23 Jun 2026
The Digital Pharma Advances Conference 2026

Most Popular
June   2026
M T W T F S S
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.